



Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2

Kateryna O. Lohachova¹, Anastasiia S. Sviatenko¹, Alexander Kyrychenko^{1*} , Volodymyr V. Ivanov¹, Thierry Langer², Sergiy M. Kovalenko¹, Oleg N. Kalugin¹

¹School of Chemistry, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine.

²Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.

ARTICLE HISTORY

Received on: 19/12/2023
Accepted on: 10/04/2024
Available Online: 05/05/2024

Key words:

COVID-19, nirmatrelvir, antiviral activity, SARS-CoV-2, M^{pro}.

ABSTRACT

A computer-aided drug design of new derivatives of nirmatrelvir, an orally active inhibitor of the main-protease (M^{pro}) of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), was performed to identify its analogs with a higher antiviral potency. The following workflow was used: first, an evolutionary library composed of 1,866 analogs was generated starting from a parent nirmatrelvir scaffold and going through small mutation, fitness scoring, ranking, and selection. Second, the generated library was preprocessed and filtered against a 3-D pharmacophore model of nirmatrelvir built from its X-ray structure in a co-crystallized complex with the M^{pro} enzyme, allowing us to reduce the chemical space to 32 active analogs. Third, structure-based molecular docking against two different enzyme structures further ranked these active candidates, so that up to eight better-binding analogs were identified. The selected hit-analogs target the M^{pro} enzymes of SARS-CoV-2 with a higher binding affinity than a parent nirmatrelvir. The main structural modifications that increase the overall inhibitory affinity are identified at the azabicyclo[3.1.0]hexane and 2-oxopyrrolidine fragments. A characteristic structural feature of the inhibitor binding with the M^{pro} active center is the similar location of the trifluoroacetyl amino fragment, which is observed for most hit-analogs. The suggested workflow of the computer-aided rational design of new antiviral noncovalent inhibitors based on the scaffold of approved drugs is a promising, extremely low-cost, and time-efficient approach for the development of new potential pharmaceutical ingredients for the treatment of Coronavirus Disease 2019.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a multisystem infection caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]. The COVID-19 pandemic has resulted in an unprecedented response from the scientific community, offering some urgent treatment based on traditional pharmacological chemistry, drug repurposing, and computational screening approaches [2,3]. Drug repurposing of small-molecule antivirals for COVID-19 treatment has been undertaken to identify potential new therapeutics to treat SARS-CoV-2 [4]. Despite the considerable amount of computational and experimental data available for the treatment of COVID-19, only

remdesivir, molnupiravir, and nirmatrelvir have been authorized by the U.S. Food and Drug Administration (FDA) as drugs for the treatment of COVID-19 [5–7]. Paxlovid is one of the first approved antiviral drugs for treating COVID-19, developed by Pfizer in 2021 [8–11]. Nirmatrelvir (PF-07321332) is the main ingredient of Paxlovid and inhibits the main protease (M^{pro}) of virus SARS-CoV-2 (Fig. 1). It is an orally bioavailable drug against SARS-CoV-2 [5,12–15], which also shows antiviral potency against other human coronaviruses [8,16,17].

Nirmatrelvir has a peptide-like structure (Fig. 1), and its co-crystallized complex with the M^{pro} protease opened up the opportunities for developing a broad family of tri- or tetrapeptide mimetics containing an electrophile capable of interacting with the catalytic cysteine [5,7]. Therefore, the structure of nirmatrelvir is a promising scaffold for the rational design of new, more effective antiviral drugs. Considering its complex multistep synthesis, we utilize an alternative approach

*Corresponding Author

Alexander Kyrychenko, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine. E-mail: a.v.kyrychenko@karazin.ua

based on a computer-aided drug design and prediction of the relationship between the structure of nirmatrelvir derivatives and their binding affinity (BA) for the active site of the M^{pro} enzyme of SARS-CoV-2.

METHODOLOGY OF RESEARCH

Computer-aided drug discovery has become a powerful tool for streamlining structure-based virtual screening of large chemical databases and offering new opportunities for the cost-effective development of new drug-like ligands [18]. However, this approach is known to be crucially dependent on used chemical spaces. There are several approaches to creating a virtual chemical library of new molecules that are structurally similar to a target structure, such as generating combinatorial libraries from approved drugs and natural products. Another approach is building an evolutionary library starting from a parent scaffold and going through small mutation, fitness scoring, ranking, and selection toward drug-like molecules [19].

Building of virtual evolutionary library

First, we generated a virtual library of nirmatrelvir analogs utilizing an evolutionary algorithm that mimics nature's evolution of drug-like compounds using DataWarrior software [20]. The procedure was as follows: the algorithm starts with a parent nirmatrelvir (**1**) (Fig. 1) called the first generation. Next, a series of similar derivatives were built by applying a minor random structural modification of a parent structure. Each new structural modification is then evaluated regarding how much it fits within up to seven customizable fitness criteria, such as molecular weight (M_w), cLogP, polar surface area (PSA) [21], molecular shape and flexibility, and so on (Table 1).

The molecular weight of a drug-like molecule is a crucial parameter that helps to correlate its biological activity with its chemical and physical properties. According to Lipinski's rule of five [22], for drugs to be orally bioavailable, M_w should be less than 500 g/mol. Nirmatrelvir has $M_w = 499$ g/mol, so the corresponding fitness criterion was set to be within 490–515 g/mol (see Table 1).

The calculated logarithm of the partition coefficient of a compound between *n*-octanol and water $\log(C_{\text{octanol}}/C_{\text{water}})$, referred to as cLogP, is one of the critical fitness criteria. It is a well-established measure of the drug's hydrophilicity. Low hydrophilicity and, hence, high cLogP leads to poor absorption or permeation. For nirmatrelvir, cLogP equals 0.98, so the corresponding fitness criterion was targeted to be within 0.8–1.2 (Table 1).

The PSA defines the surface sum over all polar atoms, such as oxygen, nitrogen, sulfur, and phosphorus, including attached hydrogens. PSA is a commonly used medicinal chemistry criterion for estimating cell permeability. Drug-like molecules with $\text{PSA} > 140 \text{ \AA}^2$ are typically poorly permeable into cell membranes. In addition, to penetrate the blood-brain barrier, PSA should be less than 60 \AA^2 . Nirmatrelvir has a PSA of 131 \AA^2 , so this fitness criterion was fixed to be $110\text{--}150 \text{ \AA}^2$.

In addition to the above criteria, to assess the shape and 3-D conformational similarity of multiple conformers of the candidate molecules, two following algorithms were applied: (i) Pharmacophore Enhanced Shape Alignment "PheSA" and

(ii) OrgFunctions Descriptor. These tools allow us to check whether any two molecules may have a compatible protein binding behavior in terms of shape, size, and flexibility (see Table 1).

Structural mutations that best fit these criteria are assigned a higher probability during the generation of new chemical space. The new analogs within the current generation are ranked according to these criteria so that the highest-ranking molecules from this generation are selected to survive and form the parent molecules for the next generation. Following this evolutionary algorithm, up to hundred generations were created with a total number of 1,866 virtual analogs.

Figure 2 shows the 2-D distribution of M_w versus cLogP in the generated library, which reveals a symmetric distribution around a central *red* point corresponding to a parent nirmatrelvir.

3-D pharmacophore screening

The generated evolutionary library is too large for conventional molecular docking against the M^{pro} enzyme. Therefore, it was subject to further preprocessing and filtering to match a five-point 3-D pharmacophore model of nirmatrelvir generated using its first available crystal structure in a complex with M^{pro} (PDB: 7VH8) [23] using LigandScout software developed by Wolber and Langer [24]. A 3-D pharmacophore model is a chemical fingerprint, which takes into account certain chemical features of a ligand, such as hydrogen bond donors, acceptors, lipophilic areas, and positively and negatively ionizable chemical groups, that describe its interaction with the surrounding binding site of a protein. Figure 3 shows the five-point pharmacophore model for nirmatrelvir, which identifies two key pharmacophoric points, such as peripheral trifluoroacetyl group and 6,6-dimethyl-3-azobicyclo[3.1.0]hexane moiety. Such a five-point 3-D pharmacophore has been used to characterize key interactions within the complex nirmatrelvir-M^{pro} [25]. Finally, applying the pharmacophore-guided screening procedure allowed us to reduce the chemical space of the evolutionary library from 1,866 to 32 active candidates.

Structure-based molecular docking

To evaluate the BA of the 32 selected active hit molecules, we applied structure-based molecular docking




Figure 1. Molecular structure of nirmatrelvir (PF-07321332).

Table 1. Customizable fitness criteria and corresponding parameters are used to build the virtual evolutionary library of nirmatrelvir's analogs.

Customizable criteria		
Number of generations	100	
Number of compounds per generation	1,024	
Number of compounds that survive generation	128	
Fitness settings		
Parameter	Setting	Weight
Molecular weight	490–515 g/mol	1.0
cLogP	0.8–1.2	1.0
Polar surface area	110–150 Å ²	1.0
Structural similarity	Flexpore	1.0
Conformational similarity	PheSA	1.0
Molecular flexibility	0.4–0.6	1.0
Molecular shape	0.3–0.5	1.0




Figure 2. 2-D plot of distributions of M_w versus cLogP parameters for the generated evolutionary library.

calculations using LigandScout software [24]. The LigandScout software uses a built-in version of AutoDock Vina 1.1 [26]. Therefore, to validate the ligand-protease docking algorithm, nirmatrelvir was re-docked, and its geometry was compared with the corresponding X-ray structure of the enzyme-bound ligand with M^{pro} (PDB: 7VH8), as shown in Figure 4. The molecular docking results for the best-binding conformation of nirmatrelvir and its experimental crystallographic structure are in good agreement, which allows us to use this method for the quantitative analysis of the M^{pro} affinity of new nirmatrelvir derivatives.

Finally, the BA of the 32 selected high-ranked nirmatrelvir analogs was evaluated by conventional molecular docking calculations against the two different X-ray structures




Figure 3. (A) 3-D five-point pharmacophore model of nirmatrelvir derived from its crystal structure in a complex with M^{pro} (PDB: 7VH8). Highlighted residues His41 and Cys145 belong to the catalytic dyad of the active site of M^{pro}. (B) Scheme of intermolecular interactions of nirmatrelvir with key surrounding residues of M^{pro}.




Figure 4. Comparison of the results of molecular docking of nirmatrelvir with its X-ray structure in the complex with M^{pro}. The geometry of nirmatrelvir incorporation into the M^{pro} main protease molecule of the SARS-CoV-2 virus (PDB: 7VH8). The catalytic amino acid residues His41 and Cys145 of the active center of the protease are shown in blue or red. The binding mode of the ligand estimated by the molecular docking is shown in green, whereas the X-ray structure is given in purple.

of the M^{pro} enzyme. The first M^{pro} structure corresponds to the protein taken from its co-crystallized complex with nirmatrelvir (PDB 7VH8). The second M^{pro} structure corresponds to the ligand-free protein measured at 310 K (PDB 7MHK) [27]. Finally, our *in silico* screening procedure allowed us to identify up to eight hits with a BA higher than that of a parent nirmatrelvir.

COMPUTATIONAL METHODS

OSIRIS DataWarrior software, version 5.5.0., was used to generate an evolutionary library and to calculate the physicochemical properties of ligands [20].

MarvinSketch was used for drawing, displaying, and characterizing chemical structures (MarvinSketch 23.1., 2023,




Figure 5. A workflow of virtual screening of nirmatrelvir analogs.




Figure 6. Molecular structure of nirmatrelvir (1) and its designed analogs, revealing the higher BA. Mutated fragments are colored in wine.

ChemAxon, <https://chemaxon.com/>, accessed on 1 February 2023).

Molecular docking was performed for selected inhibitors against the M^{pro} protease of SARS-CoV-2. The spatial structure of the M^{pro} protease was taken from the Protein Data Bank (PDB ID: 7VH8) [23]. The ligand and water molecules were removed. Semi-flexible molecular docking calculations were performed using the AutoDock Vina 1.1 [26] built into the LigandScout software (version 4.4.9) [24], in which the receptor was kept rigid, and the ligand molecules were conformationally flexible. For each ligand, three independent runs were performed. The best docking mode corresponds to the highest ligand BA. Molecular graphics and visualization were performed using LigandScout 4.4.9 and VMD 1.9.3 [28].

RESULT AND DISCUSSION

Identifying novel (i.e., never-before-seen) drug-like compounds, relying upon *in silico* screening of “in stock” and “on demand” virtual libraries of compounds, is a critical and rate-limiting step in drug discovery [29–32]. Therefore, alternative strategies have also been suggested

based on generating new chemical spaces, originating from already approved drugs and following its consequent hit-to-lead optimization [33,30,34,19,35–37]. Herein, we report structure-based optimization of new noncovalent inhibitors against the coronavirus SARS-CoV-2 M^{pro} , starting from the FDA-approved drug nirmatrelvir. The X-ray structure of M^{pro} -bound nirmatrelvir was used as a targeting scaffold to guide the optimization procedure. A series of structural mutations of nirmatrelvir were suggested, accompanied by adjustments of corresponding physicochemical properties, such as M_w , cLogP, and PSA, respectively. Our virtual screening workflow and hit-selecting protocols of the best-binding analogs of nirmatrelvir are summarized in Figure 5.

The generated evolutionary library composed of 1,866 nirmatrelvir-like compounds was optimized by seven physicochemical fitness criteria (Table 1). However, filtering this library through the five-point 3-D pharmacophore model of nirmatrelvir (Fig. 3) discarded the vast majority of generated structures, while only an exceedingly small subset of 32 top-scoring compounds survived for further analysis.

To evaluate the BA of these 32 active hit candidates against M^{pro} , we applied conventional molecular docking calculations using LigandScout software. Our docking results demonstrate that up to eight designed analogs revealed a BA higher than a parent nirmatrelvir did, as summarized in Figure 6 and Table 2.


Energetic characteristics of the protease-ligand interaction and some physicochemical properties of hit-analogs are summarized in Table 2. The following parameters were selected as BA criteria: (1) BA estimated by the AutoDock Vina docking algorithm. This parameter is very common and allows a direct comparison with the previously published BAs of a large number of ligands revealing the inhibitory activity against SARS-CoV-2 coronavirus proteases [38–42]. (2) Binding enthalpy (BE) for the protein–ligand complex calculated using the MMF94 empirical force field. This parameter is calculated as the difference between the potential energy of the complex and the energy of the starting substances. (3) Binding affinity score (BAS) calculated by the LigandScout software package. BAS takes into account both the protein-ligand BE and the environmental effect. This parameter is considered the most representative and was therefore chosen for the selection of hit ligands [43].

The calculated value of the binding enthalpy for nirmatrelvir equals -10.4 kcal/mol, which agrees well with the experimentally determined value of isothermal titration calorimetry -10.75 kcal/mol [44]. The experimental free energy of nirmatrelvir binding to M^{pro} is -11.2 kcal/mol, which is somewhat underestimated to be -7.2 kcal/mol by AutoDock Vina.

Figure 7 shows the typical binding modes of nirmatrelvir and its hit-analogs at the active site of the M^{pro} enzyme. In conventional docking, all the inhibitors utilized a noncovalent mode of action. Notably, analogs 2–6 bind to the M^{pro} pocket by its N-terminal trifluoroacetamide moiety. The results of Table 2 and Figure 7 indicate that minor structural modifications of the parent nirmatrelvir 1, such as the replacement of 3-ethyl-2-oxopyrrolidine by 3-propyl-2-oxopyrrolidine in 2, lead to an

Table 2. Molecular docking results of nirmatrelvir and its analogs against two different X-ray structures (PDB ID: 7VH8 and 7MHK) and their physicochemical parameters.


Ligands	AutoDock Vina BA (kcal/mol)		MMF94 BE (kcal/mol)		LigandScout BA score		Mw (g/mol)	cLogP	PSA (Å ²)
	7VH8	7MHK	7VH8	7MHK	7VH8	7MHK			
1	-7.2	-6.9	-10.4	-14.0	-13.6	-16.1	499	0.98	131
2	-7.5	-6.9	-11.3	-23.0	-22.3	-14.6	513	1.43	131
3	-7.8	-6.5	-13.1	-4.4	-20.1	-19.4	502	2.08	108
4	-7.8	-6.6	-15.7	-22.6	-19.1	-14.7	499	1.03	131
5	-7.2	-6.6	-20.9	-25.1	-17.3	-18.3	473	0.73	123
6	-7.7	-6.3	-24.3	-18.2	-15.7	-16.2	486	1.68	128
7	-8.6	-6.6	-38.9	-22.2	-15.6	-18.1	502	2.08	108
8	-7.4	-6.6	-25.5	-17.9	-14.6	-19.5	501	1.42	131
9	-8.2	-6.6	-15.6	-9.8	-13.7	-19.7	502	1.93	108

**Figure 7.** Best-binding modes of nirmatrelvir (1) and its analogs at the active site of the M^{pro} enzyme estimated by molecular docking calculations.

increase of BE and BAS from -13.6 to -22.3, respectively. It suggests the possibility of further modification on these sites to increase the binding strength with M^{pro}.

A characteristic structural feature of the inhibitor binding with the active center of M^{pro} is the similar location of the trifluoroacetyl-amino fragment, which is observed in derivatives 1-6 presented in Figure 7. Thus, the overall BA of these inhibitors is increased due to structural modifications of the opposite part of the molecule. The main structural modifications that occurred in inhibitors 2-9 are located in two fragments of the nirmatrelvir molecule, namely, in the azabicyclo[3.1.0]hexane and oxopyrrolidine fragments (Fig. 7).

Figure 8A and C show that derivatives 7 and 9 increase in BAS from -13.6 to -15.6 and -13.7 (Table 2),

**Figure 8.** Binding modes of some nirmatrelvir's analogs at the active site of the M^{pro} enzyme estimated by molecular docking calculations.

respectively. A characteristic structural feature of both derivatives is the replacement of the 2-oxopyrrolidine ring with a 2-oxopiperidine ring. However, such a modification obviously does not contribute to increasing the antiviral effect of nirmatrelvir derivatives.

Finally, it has been reported that a conventional docking procedure utilizing an enzyme structure from a corresponding co-crystallized protein-ligand complex is somewhat affected by the structural plasticity of an enzyme and the presence of a bulky ligand bound at the active center [45-47]. Therefore, the selected 32 hit analogs were also re-docked against the ligand-free room-temperature X-ray structure of M^{pro} (PDB 7MHK), as summarized in Figure S1 and Table 2. These results suggest that the ligand binding to the M^{pro} structure, measured at 310 K, is characterized by some decrease in the absolute BA. However, our molecular docking demonstrates that, in terms of BAS, the most identified hit analogs, except 2 and 4, revealed promising binding parameters.

CONCLUSION

Herein, we carried out a computer-aided drug design intending to identify new analogs of nirmatrelvir capable of a higher antiviral potency against the coronavirus SARS-CoV-2. First, we generated a new virtual library composed of 1,866 nirmatrelvir analogs, which was further preprocessed and filtered

against a 3-D pharmacophore model of a parent nirmatrelvir, reducing the chemical space to 32 active analogs. Second, conventional structure-based molecular docking against the two different enzyme structures allowed us to identify up to eight nirmatrelvir analogs with high-ranked binding characteristics. The selected hits target the M^{Pro} enzymes of SARS-CoV-2 with a higher BA than a parent nirmatrelvir. We found that the main structural modifications that increase the overall inhibitory effect of novel analogs are localized in the azabicyclo[3.1.0]hexane and 2-oxopyrrolidine fragments. Finally, the suggested workflow of the rational design of new antiviral noncovalent inhibitors based on the scaffold of approved drugs is a promising, extremely low-cost, and time-efficient approach for developing new potential pharmaceutical ingredients for the treatment of COVID-19.

AUTHOR CONTRIBUTIONS

K.O.L. was responsible for the conceptualization, formal analysis, investigation, methodology, and writing of the original draft. A.S.S. contributed to the investigation and methodology. A.K., V.V.I., T.L., S.M.K., and O.N.K. were responsible for methodology, writing of the original draft, and the review and editing of the article.

FINANCIAL SUPPORT

K.O.L., A.K., V.V.I., S.M.K., and O.N.K. acknowledge Grant № 42/0062 (2021.01/0062) “Molecular design, synthesis and screening of new potential antiviral pharmaceutical ingredients for the treatment of infectious diseases COVID-19” from the National Research Foundation of Ukraine.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest in relation to this research, whether financial, personal, authorship, or otherwise, that could affect the research and its results presented in this paper.

ETHICAL APPROVALS

This study does not involve experiments on animals or human subjects.

DATA AVAILABILITY

All data generated and analyzed are included in this research article.

PUBLISHER'S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES

1. La Monica G, Bono A, Lauria A, Martorana A. Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives. *J Med Chem.* 2022;65(19):12500–34.
2. da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, *et al.* Two years into the COVID-19 pandemic: lessons learned. *ACS Infect Dis.* 2022;8(9):1758–814.
3. Mousavi H, Zeynizadeh B, Rimaz M. Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 M^{Pro} and PL^{Pro}. *Bioorg Chem.* 2023;135:106390.
4. Galindez G, Matschinske J, Rose TD, Sadegh S, Salgado-Albarrán M, Späth J, *et al.* Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. *Nat Comput Sci.* 2021;1(1):33–41.
5. Allais C, Connor CG, Do NM, Kulkarni S, Lee JW, Lee T, *et al.* Development of the commercial manufacturing process for Nirmatrelvir in 17 months. *ACS Cent Sci.* 2023;9(5):849–57. doi: <https://doi.org/10.1021/acscentsci.3c00145>
6. Fischer C, Feys JR. SARS-CoV-2 M^{Pro} inhibitors: achieved diversity, developing resistance and future strategies. *Future pharmacol.* 2023;3(1):80–107.
7. Lamb YN. Nirmatrelvir plus ritonavir: first approval. *Drugs.* 2022;82(5):585–91.
8. Blair HA. Nirmatrelvir plus ritonavir in COVID-19: a profile of its use. *Drug Therap Perspect.* 2023;39(2):41–7.
9. Halford B. The path to Paxlovid. *ACS Cent Sci.* 2022;8(4):405–7.
10. Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E. Paxlovid: mechanism of action, synthesis, and *in silico* study. *BioMed Res Intern.* 2022;2022:7341493.
11. Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, *et al.* An oral SARS-CoV-2 M^{Pro} inhibitor clinical candidate for the treatment of COVID-19. *Science.* 2021;374(6575):1586–93.
12. Dawood AA. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M^{Pro} and antiviral drugs (nirmatrelvir and ritonavir). *Adv Med Sci.* 2023;68(1):1–9.
13. Duveau DY, Thomas CJ. The remarkable selectivity of nirmatrelvir. *ACS Pharm Transl Sci.* 2022;5(6):445–7.
14. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. *BMJ.* 2021;375:n2713.
15. Yang KS, Leeuwon SZ, Xu S, Liu WR. Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir. *J Med Chem.* 2022;65(13):8686–98.
16. Li J, Wang Y, Solanki K, Atre R, Lavrijsen M, Pan Q, *et al.* Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. *Antiviral Res.* 2023;211:105555.
17. Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data. *Viruses.* 2023;15(4):976.
18. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. *Nature.* 2023;616(7958):673–85.
19. Lyu J, Irwin JJ, Shoichet BK. Modeling the expansion of virtual screening libraries. *Nat Chem Biol.* 2023;19:712–18. doi: <https://doi.org/10.1038/s41589-022-01234-w>
20. Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. *J Chem Inf Model.* 2015;55(2):460–73.
21. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. *J Med Chem.* 2000;43(20):3714–7.
22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Delivery Rev.* 2001;46(1):3–26.
23. Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y, *et al.* Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. *Prot Cell.* 2021;13(9): 689–93.
24. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. *J Chem Inf Model.* 2005;45(1):160–9.

25. Hayek-Orduz Y, Vásquez AF, Villegas-Torres MF, Caicedo PA, Achenie LEK, González Barrios AF. Novel covalent and non-covalent complex-based pharmacophore models of SARS-CoV-2 main protease (Mpro) elucidated by microsecond MD simulations. *Sci Rep.* 2022;12(1):14030.
26. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem.* 2010;31(2):455–61.
27. Ebrahim A, Riley BT, Kumaran D, Andi B, Fuchs MR, McSweeney S, *et al.* The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (Mpro). *IUCrJ.* 2022;9(5):682–94.
28. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol Graph.* 1996;14(1):33–8.
29. Chatterjee A, Walters R, Shafi Z, Ahmed OS, Sebek M, Gysi D, *et al.* Improving the generalizability of protein-ligand binding predictions with AI-Bind. *Nat Commun.* 2023;14(1):1989.
30. Gentile F, Fernandez M, Ban F, Ton AT, Mslati H, Perez CF, *et al.* Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules. *Chem Sci.* 2021;12(48):15960–74.
31. Joshi RP, Schultz KJ, Wilson JW, Krueel A, Varikoti RA, Kombala CJ, *et al.* AI-Accelerated design of targeted covalent inhibitors for SARS-CoV-2. *J Chem Inf Model.* 2023;63(5):1438–53.
32. Zahrychuk HY, Gladkov ES, Kyrychenko AV, Poliovyi DO, Zahrychuk OM, Kucher TV, *et al.* Structure-based rational design and virtual screening of valsartan drug analogs towards developing novel inhibitors of Angiotensin II type 1 receptor. *Biointerface Res Appl Chem.* 2023;13(5):440.
33. Brewitz L, Dumjahn L, Zhao Y, Owen CD, Laidlaw SM, Malla TR, *et al.* Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine. *J Med Chem.* 2023;66(4):2663–80.
34. Hou N, Shuai L, Zhang L, Xie X, Tang K, Zhu Y, *et al.* Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro. *ACS Cent Sci.* 2023;9(2):217–27.
35. Pozzi C, Vanet A, Francesconi V, Tagliacuzzi L, Tassone G, Venturelli A, *et al.* Antitarget, anti-SARS-CoV-2 leads, drugs, and the drug discovery–genetics alliance perspective. *J Med Chem.* 2023;66(6):3664–702.
36. Saramago LC, Santana MV, Gomes BF, Dantas RF, Senger MR, Oliveira Borges PH, *et al.* AI-Driven discovery of SARS-CoV-2 main protease fragment-like inhibitors with antiviral activity *in vitro*. *J Chem Inf Model.* 2023;63(9):2866–80.
37. Snizhko AD, Kyrychenko AV, Gladkov ES. Synthesis of novel derivatives of 5,6,7,8-tetrahydro-quinazolines using of α -aminoamidines and *in silico* screening of their biological activity. *Int J Mol Sci.* 2022;23(7):3781.
38. Al-Khafaji K, Al-Duhaidahawi D, Taskin Tok T. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. *J Biomol Struct Dyn.* 2020;39(9):3387–95.
39. Ghahremanpour MM, Tirado-Rives J, Deshmukh M, Ippolito JA, Zhang CH, Cabeza de Vaca I, *et al.* Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. *ACS Med Chem Lett.* 2020;11(12):2526–33.
40. Llanos MA, Gantner ME, Rodriguez S, Alberca LN, Bellera CL, Talevi A, *et al.* Strengths and weaknesses of docking simulations in the SARS-CoV-2 era: the main protease (Mpro) case study. *J Chem Inf Model.* 2021;61(8):3758–70.
41. Mengist HM, Dilnessa T, Jin T. Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. *Front Chem.* 2021;9:622898.
42. Thangavel N, Albratty M. Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors. *Arab J Chem.* 2022;15(12):104334.
43. Evseeva LV, Ivanov VV, Karpina VR, Kovalenko SS, Kuznetsov IE, Langer T, *et al.* The virtual screening application for searching potential antiviral agents to treat COVID-19 disease. *J Org Pharm Chem.* 2020;18(2):3–15.
44. Kneller DW, Li H, Phillips G, Weiss KL, Zhang Q, Arnould MA, *et al.* Covalent nirmatrelvir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease. *Nat Commun.* 2022;13(1):2268.
45. Kneller DW, Phillips G, O'Neill HM, Jedrzejczak R, Stols L, Langan P, *et al.* Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. *Nat Commun.* 2020;11(1):3202.
46. Pathak N, Chen YT, Hsu YC, Hsu NY, Kuo CJ, Tsai HP, *et al.* Uncovering flexible active site conformations of SARS-CoV-2 3CL proteases through protease pharmacophore clusters and COVID-19 drug repurposing. *ACS Nano.* 2021;15(1):857–72.
47. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, *et al.* Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science.* 2020;368(6489):409.

How to cite this article:

Lohachova KO, Sviatenko AS, Kyrychenko A, Ivanov VV, Langer T, Kovalenko SM, Kalugin ON. Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of coronavirus SARS-CoV-2. *J Appl Pharm Sci.* 2024;14(05):232–239.

SUPPLEMENTARY MATERIAL




Figure S1. Best-binding modes of nirmatrelvir (1) and its analogs at the active site of the root-temperature M^{pro} enzyme structure estimated by molecular docking calculations